BRCA2 and cancer: Although BRCA1- or BRCA2-deficient cancer cells exhibiting defects in homologous recombination (HR deficiency) are hypersensitive to PARP inhibitors [33,34] through the mechanism of synthetic lethality [35], acquired resistance to PARP inhibitors was observed in patients with HR deficient HGSOC.